Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

3 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for severe respiratory illnesses, including severe influenza, severe and moderate COVID-19 infection, and severe community-acquired pneumonia (CAP). The trial aims to find out how different treatments can improve the health outcomes of patients who are seriously ill and admitted to the hospital, especially those in intensive care units (ICUs). The main goal is to see if these treatments can reduce the number of deaths within 90 days for patients with severe CAP and during a pandemic, to improve outcomes for those with acute illnesses due to suspected or confirmed pandemic infections.

The study involves several medications, including baricitinib, piperacillin sodium, tazobactam sodium, tocilizumab, amoxicillin sodium, clavulanic acid, azithromycin, levofloxacin, erythromycin lactobionate, baloxavir marboxil, oseltamivir, moxifloxacin, dexamethasone, imatinib, ceftriaxone, hydrocortisone, and roxithromycin. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The trial is designed to adapt and change based on the results as they come in, which helps researchers find the best treatment options more quickly.

Participants in the study will receive one or more of these treatments, and their health will be monitored over time to see how they respond. The study will look at various outcomes, such as survival rates, the length of time spent in the ICU, and the number of days patients are free from needing a ventilator or other organ support. The trial is expected to continue until March 2026, with the aim of providing valuable information on how to best treat these serious respiratory conditions.

1 joining the study

Upon joining the study, the patient is admitted to the intensive care unit (ICU) with severe community-acquired pneumonia (CAP) or a suspected pandemic infection.

The patient must be an adult and admitted to the ICU within 48 hours of hospital admission with symptoms like difficulty breathing, cough, or chest pain, along with radiological evidence of infection.

2 initial assessment

The patient undergoes an initial assessment to confirm eligibility, which includes checking for the need for ventilatory support or infusion of medications to support heart function.

3 treatment allocation

The patient is randomly assigned to receive one or more of the following medications, depending on their specific condition and the study’s requirements:

Baricitinib (oral use), Piperacillin and Beta-lactamase Inhibitor (IV infusion), Tocilizumab (IV infusion), Amoxicillin and Beta-lactamase Inhibitor (IV injection or infusion), Azithromycin (oral or IV use), Levofloxacin (IV infusion), Erythromycin Lactobionate (IV injection or infusion), Baloxavir Marboxil (oral use), Clarithromycin (oral or IV use), Oseltamivir (oral use), Moxifloxacin (IV infusion), Dexamethasone (oral or IV use), Imatinib (oral use), Ceftriaxone (IV injection or infusion), Hydrocortisone (IV injection or infusion), Roxithromycin (oral use).

4 treatment administration

The patient receives the assigned treatment according to the study protocol, which includes specific dosages and administration routes for each medication.

The duration and frequency of administration depend on the patient’s response and the study’s guidelines.

5 monitoring and follow-up

The patient’s health is closely monitored throughout the study, with regular assessments to evaluate the effectiveness of the treatment.

The primary goal is to improve outcomes, such as reducing mortality within 90 days and minimizing the need for organ support.

6 study completion

The study concludes with a final assessment of the patient’s health status, including survival and quality of life measures.

The study aims to gather data on the effectiveness of various treatments for severe CAP and pandemic infections.

Who Can Join the Study?

  • The patient must be an adult who is admitted to an ICU (Intensive Care Unit) for severe community-acquired pneumonia (CAP) within 48 hours of arriving at the hospital. The patient should have symptoms like sudden difficulty breathing, cough, or sharp chest pain, along with X-ray evidence of a new lung infection.
  • Within 48 hours of being admitted to the ICU, the patient should be receiving support for their organs. This can include help with breathing using machines (ventilatory support) or medications that help the heart pump blood (vasopressors or inotropes).
  • For patients affected by a pandemic: The patient must be an adult admitted to the hospital with a sudden illness due to a suspected or confirmed pandemic infection.
  • There may be additional specific requirements outlined in a separate document called a Domain Specific Appendix (DSA).

Who Cannot Join the Study?

  • Patients who do not have severe influenza, which is a very serious flu infection.
  • Patients who do not have severe or moderate COVID-19 infection, which is a serious or moderate illness caused by the coronavirus.
  • Patients who do not have severe community-acquired pneumonia (CAP), which is a serious lung infection caught outside of a hospital.
  • Patients who are not admitted to an ICU, which is the Intensive Care Unit, a special part of the hospital for very sick patients.
  • Patients who are not adults, meaning they are not in the age range of 18 years and older.
  • Patients who are part of a vulnerable population, which means they are not in a group that needs special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
CHU de Liege Liege Belgium
Zuyderland Medisch Centrum Stichting Geleen The Netherlands
IRCCS Humanitas Research Hospital Rozzano Italy
Frisius Heerenveen The Netherlands
University Hospital Jena KöR Jena Germany
Universitaet Leipzig Leipzig Germany
Stichting OLVG Amsterdam The Netherlands
Algemeen Stedelijk Ziekenhuis Campus Aalst Aalst Belgium

Other Sites

Site Name City Country Status
Ziekenhuis Gelderse Vallei Stichting Ede The Netherlands
Haga Hospital Hague The Netherlands
Hopital Tenon Paris France
Noordwest Ziekenhuisgroep Stichting Alkmaar The Netherlands
Universitair Ziekenhuis Gent Gent Belgium
Jeroen Bosch Ziekenhuis Stichting s-Hertogenbosch The Netherlands
Canisius Wilhelmina Ziekenhuis Nijmegen The Netherlands
Amphia Hospital Breda The Netherlands
University Hospital Waterford Waterford Ireland
Medisch Spectrum Twente Enschede The Netherlands
Diakonessenhuis Stichting Utrecht The Netherlands
Ziekenhuisgroep Twente Stichting Almelo The Netherlands
Ikazia Ziekenhuis Rotterdam The Netherlands
Flevoziekenhuis Stichting Almere The Netherlands
Bernhoven B.V. Uden The Netherlands
Maxima Medisch Centrum Veldhoven The Netherlands
KBC Zagreb Zagreb Croatia
Centre Hospitalier Pays de Morlaix Morlaix France
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan Italy
Ospedale San Raffaele S.r.l. Milan Italy
Universitair Medisch Centrum Utrecht Utrecht The Netherlands
Centre Hospitalier Le Mans Le Mans France
Tartu University Hospital Tartu Estonia
Maasstad Ziekenhuis Stichting Rotterdam The Netherlands
Saarland University Hospital Homburg Germany
St. Antonius Ziekenhuis Nieuwegein The Netherlands
University Hospital Galway Galway Ireland
Meander Medical Center Amersfoort The Netherlands
Fakultni Nemocnice Kralovske Vinohrady Prague Czechia
Sint Franciscus Vlietland Groep Stichting Rotterdam The Netherlands
Deventer Ziekenhuis Deventer The Netherlands
Centre Hospitalier Universitaire De Nantes Nantes France
Centro Hospitalar De Lisboa Ocidental E.P.E. Lisbon Portugal
Slingeland Ziekenhuis Doetinchem The Netherlands
Centre Hospitalier Universitaire De Rennes Rennes France
Centre Hospitalier De Dax Dax France
Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione S.r.l. Palermo Italy
Centre Hospitalier Simone Veil De Beauvais Beauvais France
Universita’ Degli Studi Di Modena E Reggio Emilia Modena Italy
Charite Research Organisation GmbH Berlin Germany
Deutsches Herzzentrum Berlin Berlin Germany
Hospital Del Mar Barcelona Spain
Universita Degli Studi Di Brescia Brescia Italy
Hospital Universitario Dr Peset Aleixandre Valencia Spain
Infectious and Tropical Diseases Hospital Dr. Victor Babes Bucharest Romania
Centre Hospitalier de Dieppe Dieppe France
Beaumont Hospital Dublin Ireland
Dijklander Ziekenhuis Hoorn The Netherlands
Clinique Saint-Pierre Ottignies (CSPO) Ottignies Belgium
Klinika Za Infektivne Bolesti Dr. Fran Mihaljevic Zagreb Croatia
Nouvel Hopital Civil Strasbourg STRASBOURG, Alsace France
Rlmhrawlv Zqfzjoxijw Szstkesya Arnhem The Netherlands
Ulxizwezmsao Mrgkaom Clzqobx Ggmtngsvo Groningen The Netherlands
Stevssqhq Mcidqrj Znqovirhbv Groningen The Netherlands
Cste Ujnisukoya Hwthsqjo Cork Ireland
Cmmxgb hcgbunevpid dd Lmly Lens France
Cxommt hjpkfgiprpk Mbyvf Melun France
Cfy Dzkwp Bobchgzkn Hrumyml Fhjrjqzz Mcwhhvgpr Dijon France
Twsvvav Haimvbzm Teplice Czechia
Uqxxpjfqww Cbbuvz Ghlkur Golnik Slovenia
Hqtnetwi db Tuoskbo Vjtru du lc Clskc Tortosa Spain
Gcsjmjc Cudwig Hcfulton Pjeqiz Pozega Croatia
Okjdtfue Iwpkhbh de Rtqxna Rimini Italy
Ldnptprpvl Zcseuxsbyx Rzpzlykt Roermond The Netherlands
Ilctnkmqdr Zmkomiardf Capelle Aan Den Ijssel The Netherlands
Cgx db Clenoxqxz Hajbuik Cjibh Midgz Ccant Charleroi Belgium
Cjpeim Hasslndzrrj Er Uqqkupvdjxbfh Dj Ljkmzqt Limoges France
Azjlctegi Uvt Amsterdam The Netherlands
Aerqylamvk Pactfbny Hviztyjf Ds Pusrb Paris France
Srnvdhwot Rwcktlc Uloxzdwkjm Mtbwjpx Cpzdwx Nijmegen The Netherlands
Ewdgwxa Usflnrpoezei Mdpaeur Cpjjehj Relhxpoeo (zovltcx Mqj Rotterdam The Netherlands
Cehjwe Hpgfwvdwgoy Rlcvqhrx Uncaupgffqjik Dv Tuyvz Tours France
Utf Mrombljankct Yvoir Belgium
Uisjgwsdqmqmvfjqsbqwj Mevwxmgj Azb Munster Germany
Ajqwvbp Uny Inarx Dv Rvrnqg Ewcycv Reggio Emilia Italy
Ugmtjlotdz Mjytgls Cfccai Higjevwenzfbfcbzz Hamburg Germany
Loxrf Uzvbhqbarjpc Mdnchih Clcinnu (gbhyf Leiden The Netherlands
Hsphusvg Uuzmrmulphchz Mglhbhd Ds Vlarcukxof Santander Spain
Ruuweklwezlsrbkx Hfjrivta Garches France
Uqmvlewcgp Hlzovbyvp Psefj Ssgyirqltcs Cnjtklx Fzvj Paris France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Recruiting
08.04.2016
Croatia Croatia
Not recruiting
08.04.2016
Czechia Czechia
Not recruiting
08.04.2016
Estonia Estonia
Not recruiting
08.04.2016
France France
Recruiting
08.04.2016
Germany Germany
Not recruiting
08.04.2016
Ireland Ireland
Recruiting
08.04.2016
Italy Italy
Not recruiting
08.04.2016
Portugal Portugal
Not recruiting
08.04.2016
Romania Romania
Not recruiting
08.04.2016
Slovenia Slovenia
Recruiting
08.04.2016
Spain Spain
Recruiting
08.04.2016
The Netherlands The Netherlands
Recruiting
08.04.2016

Trial locations

Azithromycin is an antibiotic used to treat various types of infections caused by bacteria. In this trial, it is being tested to see if it can help improve outcomes for patients with severe community-acquired pneumonia (CAP) who are admitted to an intensive care unit (ICU).

Hydrocortisone is a corticosteroid medication that helps reduce inflammation in the body. It is being studied in this trial to determine if it can improve survival rates for patients with severe CAP by reducing inflammation in the lungs.

Vitamin C is a vitamin that is important for the immune system and overall health. In this trial, it is being evaluated to see if high doses can help improve the recovery of patients with severe CAP by boosting their immune response.

Simvastatin is a medication typically used to lower cholesterol levels. In this trial, it is being investigated to see if it has additional benefits in reducing inflammation and improving outcomes for patients with severe CAP.

Interferon Beta-1a is a medication that is used to treat multiple sclerosis by modulating the immune system. In this trial, it is being tested to see if it can help improve the immune response and outcomes for patients with severe CAP during a pandemic.

Severe Influenza – Severe influenza is a viral infection that affects the respiratory system, causing symptoms such as high fever, body aches, fatigue, and cough. It progresses rapidly, often leading to complications like pneumonia, especially in vulnerable populations such as the elderly or those with weakened immune systems. The virus spreads through respiratory droplets, making it highly contagious. In severe cases, it can cause significant respiratory distress and require hospitalization. The body’s immune response to the virus can also lead to inflammation and further complications. Recovery time varies, but severe cases can take weeks to resolve fully.

Severe and Moderate COVID-19 Infection – COVID-19 is a respiratory illness caused by the SARS-CoV-2 virus, with symptoms ranging from mild to severe. Severe cases often involve difficulty breathing, persistent chest pain, and confusion, potentially leading to acute respiratory distress syndrome (ARDS). The disease progresses as the virus replicates in the body, causing inflammation and damage to the lungs and other organs. Moderate cases may involve symptoms like fever, cough, and fatigue, but without the severe respiratory distress seen in more critical cases. The virus spreads easily through respiratory droplets, making it highly contagious. The progression and severity can vary widely among individuals.

Severe Community Acquired Pneumonia (CAP) – Severe community-acquired pneumonia is a lung infection acquired outside of a hospital setting, characterized by inflammation of the air sacs in one or both lungs. It often presents with symptoms such as cough, fever, chills, and difficulty breathing. The infection can be caused by bacteria, viruses, or fungi, with bacterial pneumonia being the most common. In severe cases, the infection can lead to complications like sepsis or respiratory failure, requiring intensive medical care. The disease progresses as the infection spreads in the lungs, causing fluid accumulation and impaired oxygen exchange. Early intervention is crucial to prevent further complications.

Trial ID:
2023-507889-89-00
Protocol code:
NCT02735707
NCT ID:
NCT02735707
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain
  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    2 1 1 1
    Germany Italy Poland Spain